Education
About Us
Working with TipRanks
Follow Us
Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
MIST Analyst Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MIST Stock 12 Month Forecast
Average Price Target
$4.50
▲(86.72% Upside)
| Highest Price Target$5.00 | Average Price Target$4.50 | Lowest Price Target$4.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$5
Buy
107.47%
Upside
Reiterated
12/05/25
Milestone Pharmaceuticals: Buy Rating Reaffirmed Amid Imminent PDUFA Date and Misunderstood CRL ImplicationsValuation and Risks. Our Buy rating and $5 price target are based on a risk-adjusted net present value analysis of Cardamyst’s potential in PSVT and AFib-RVR, using a discounted cash flow (DCF) model. We apply a weighted average cost of capital (WACC) of 12.1% and an exit multiple of 15.5x on our 2031 forecasts. We assign a 60% probability of success for PSVT and 25% for AFib-RVR. We remain confident in Cardamyst’s commercial potential, particularly in PSVT, where we project peak U.S. sales of $306M (risk adjusted) and AFib-RVR risk adjusted sales of $71M at peak currently.
TD Cowen
―
Hold
―
Reiterated
11/13/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (NASDAQ: CDXS), Milestone Pharmaceuticals (NASDAQ: MIST) and Astria Therapeutics (NASDAQ: ATXS)We think MIST likely could have more visibility into timing to corporate breakeven after both tranches are exercised. Etripamil pSVT NDA 2025, MIST announced the FDA accepted their response to the CMC issues raised in the etripamil CRL. The agency assigned a new PDUFA date of Dec 13, 2025. Importantly, the FDA did not raise any concerns regarding the clinical package of the etripamil NDA.
Wells Fargo
$4
Buy
65.98%
Upside
Reiterated
11/13/25
Piper Sandler
$4
Buy
65.98%
Upside
Reiterated
07/16/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$5
Buy
107.47%
Upside
Reiterated
12/05/25
Milestone Pharmaceuticals: Buy Rating Reaffirmed Amid Imminent PDUFA Date and Misunderstood CRL ImplicationsValuation and Risks. Our Buy rating and $5 price target are based on a risk-adjusted net present value analysis of Cardamyst’s potential in PSVT and AFib-RVR, using a discounted cash flow (DCF) model. We apply a weighted average cost of capital (WACC) of 12.1% and an exit multiple of 15.5x on our 2031 forecasts. We assign a 60% probability of success for PSVT and 25% for AFib-RVR. We remain confident in Cardamyst’s commercial potential, particularly in PSVT, where we project peak U.S. sales of $306M (risk adjusted) and AFib-RVR risk adjusted sales of $71M at peak currently.
TD Cowen
―
Hold
―
Reiterated
11/13/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (NASDAQ: CDXS), Milestone Pharmaceuticals (NASDAQ: MIST) and Astria Therapeutics (NASDAQ: ATXS)We think MIST likely could have more visibility into timing to corporate breakeven after both tranches are exercised. Etripamil pSVT NDA 2025, MIST announced the FDA accepted their response to the CMC issues raised in the etripamil CRL. The agency assigned a new PDUFA date of Dec 13, 2025. Importantly, the FDA did not raise any concerns regarding the clinical package of the etripamil NDA.
Wells Fargo
$4
Buy
65.98%
Upside
Reiterated
11/13/25
Piper Sandler
$4
Buy
65.98%
Upside
Reiterated
07/16/25
Best Analysts Covering Milestone Pharmaceuticals
1 Month
xxx
Success Rate
7/13 ratings generated profit
Average Return
+0.67%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of +0.67% per trade.
3 Months
xxx
Success Rate
6/13 ratings generated profit
Average Return
-3.67%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of -3.67% per trade.
1 Year
Success Rate
6/13 ratings generated profit
Average Return
-12.08%
reiterated a buy rating 5 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -12.08% per trade.
2 Years
xxx
Success Rate
6/13 ratings generated profit
Average Return
-2.53%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 46.15% of your transactions generating a profit, with an average return of -2.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MIST Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Nov 25
Dec 25
Strong Buy
5
5
5
5
5
Buy
0
0
0
0
0
Hold
4
3
3
3
2
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
8
8
8
7
Each month's total comprises the sum of three months' worth of ratings.
MIST Financial Forecast
MIST Stock Forecast FAQ
What is MIST’s average 12-month price target, according to analysts?
Based on analyst ratings, Milestone Pharmaceuticals’s 12-month average price target is 4.50.
What is MIST’s upside potential, based on the analysts’ average price target?
Milestone Pharmaceuticals has 86.72% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MIST a Buy, Sell or Hold?
Milestone Pharmaceuticals has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
What is Milestone Pharmaceuticals’s price target?
The average price target for Milestone Pharmaceuticals is 4.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $5.00 ,the lowest forecast is $4.00. The average price target represents 86.72% Increase from the current price of $2.41.
The highest analyst price target is $5.00 ,the lowest forecast is $4.00. The average price target represents 86.72% Increase from the current price of $2.41.
What do analysts say about Milestone Pharmaceuticals?
Milestone Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of MIST?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.